SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133(2): 144153.
  • 2
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915920.
  • 3
    Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19(8): 858868.
  • 4
    When Should Multi-Site Electronic Healthcare Database Surveillance Systems Use Case-Based Designs For Medical Product Safety Monitoring?: Working Group on Case-Based Approaches for the Methods Core of the Mini-Sentinel Initiative; 2011.
  • 5
    Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999; 10(1): 3748.
  • 6
    Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011; 173(12): 14041413.
  • 7
    Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20(4): 512522.
  • 8
    Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120(23): 23222329.
  • 9
    Schneeweiss S, Patrick AR, Solomon D, et al. The comparative safety of antidepressant agents in children regarding suicide attempts and suicides. Pediatrics 2010; 125(5): 876888.
  • 10
    Schneeweiss S, Patrick AR, Solomon D, et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: A propensity score-adjusted analysis of 9 years of data. Arch Gen Psych 2010; 67(5): 497506.
  • 11
    Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303(14): 14011409.
  • 12
    Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of Death and Hospitalization for Major Medical Events after Initiation of Psychotropic Medications in Older Adults Admitted to Nursing Homes. Can Med Assoc J. 2011; 183: E411E419.
  • 13
    Toh S, García Rodríguez LA, Hernan MA. Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharamcoepidemiol Drug Saf 2011; 20: 849857.
  • 14
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21): 15201528, 1522 p following 1528.
  • 15
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284(10): 12471255.
  • 16
    Rassen JA, Doherty M, Huang W, Schneeweiss S. HD Pharamcoepi Web Site. 2011; http://www.hdpharmacoepi.org
  • 17
    Bross IDJ. Spurious effects from an extraneous variable. J Chronic Dis 1966; 19(637–47).
  • 18
    Sturmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol 2010; 172(7): 843854.
  • 19
    Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf 2010; 19: 848857.
  • 20
    Mahalanobis PC. On the generalized distance in statistics. Proc Natl Inst Sci India 1936; 12: 4955.
  • 21
    Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables II: in 25 variations, the physician prescribing preference generally was strong and reduced imbalance. J Clin Epidemiol 2009; 62(12): 12331241.
  • 22
    Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007; 26(1): 2036.
  • 23
    Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127(8 Pt 2): 757763.
  • 24
    Judkins DR, Morganstein D, Zador P, Piesse A, Barrett B, Mukhopadhyay P. Variable selection and raking in propensity scoring. Stat Med 2007; 26(5): 10221033.
  • 25
    Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol 1993; 137(1): 18.
  • 26
    Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology 2003; 14(3): 300306.
  • 27
    Pearl J. On a class of bias-amplifying variables that endanger effect estimates. Paper presented at: Proceedings of the Twenty-Sixth Conference on Uncertainty in Artificial Intelligence; AUAI, Corvallis, OR, 2010.
  • 28
    Brookhart MA, Sturmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010; 48(6 Suppl): S114120.
  • 29
    Liu W, Brookhart MA, Setoguchi S. Impact of collider-stratification bias (M-bias) in pharmacoepidemiologic studies: a simulaiton study. Pharmacoepidemiol Drug Saf 2010; 19(S1): S212.
  • 30
    Myers J. Effects of adjusting for instrumental variables on bias and variance of effect estimates. Am J Epidemiol 2011; 174: 12131222.
  • 31
    Pearl J. Invited Commentary: Understanding Bias Amplification. 2011; http://bayes.cs.ucla.edu/csl_papers.html. [30 June 2011].
  • 32
    Angrist JD, Imbens G, Rubin DB. Identifcation of causal effects using instrumental variables. JASA 1996; 94(434): 444455.
  • 33
    Rassen JA, Brookhart MA, Mittleman MA, Glynn RJ, Schneeweiss S. Instrumental variables I: exploiting quasi-random treatment choice to construe causal relationships. J Clin Epidemiol 2009; 62(12): 12261232.
  • 34
    Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010; 19: 537554.
  • 35
    Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: Methodological challenges and implications for drug development. Clin Pharmacol Ther 2011; 90: 777790.
  • 36
    Pharamcoepidemiology Toolbox version 2 [computer program]. Boston, MA, 2011.
  • 37
    Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154(9): 854864.
  • 38
    Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. Pharmacoepidemiol Drug Saf 2010; 19(8): 848857.
  • 39
    Rassen JA, Solomon DH, Curtis LH, Herrington L, Schneeweiss S. Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care 2010; 48(6 Suppl): S8389.
  • 40
    Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf 2011. DOI: 10.1002/pds.2256. (in press)
  • 41
    Kloss S. Propensity Score & High-Dimensional Propensity Score Methods in Observational Studies based on Administrative Data of Statutory Health Insurances. Bremen, Universität Bremen, 2010.
  • 42
    Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120(23): 23222329.